Skip to content
    Reviews

    Systemic Treatment Intensification Beyond CCRT in Locally Advanced Cervical Cancer

    Cheng et alCancer management and research

    Systemic Treatment Intensification Beyond CCRT in Locally Advanced Cervical Cancer
    Concurrent chemoradiotherapy (CCRT) remains the standard of care for locally advanced cervical cancer (LACC); however, 30% to 40% of patients experience disease recurrence, driving the exploration of systemic treatment intensification beyond CCRT alone. A critical review of clinical trials indexed in PubMed, Embase, and the Cochrane Library through January 2026 categorized intensification approaches by timing into neoadjuvant, concurrent, and adjuvant strategies.
    Historically, adjuvant chemotherapy regimens failed to show survival advantages and often resulted in added toxicity without therapeutic efficacy, as observed in the OUTBACK trial. Similarly, adding further concurrent cytotoxic agents to CCRT has not consistently improved clinical outcomes and carries a risk of increased toxicity.
    In contrast, recent Phase III trials have demonstrated survival benefits with specific intensification paradigms. Notably, induction chemotherapy preceding CCRT (INTERLACE) and pembrolizumab administered concurrently with CCRT and continued as maintenance therapy (KEYNOTE-A18) both demonstrated significant improvements in overall survival. While CCRT remains the foundational cornerstone of management, clinical adoption of systemic intensification requires adherence to specific tested regimens, eligibility criteria, and toxicity profiles. Additionally, the clinical utility of PD-L1-based patient selection and the independent contribution of adjuvant immunotherapy warrant further validation.

    Key Takeaways

    • Induction chemotherapy followed by CCRT (INTERLACE) and pembrolizumab combined with CCRT followed by maintenance (KEYNOTE-A18) demonstrated significant improvements in overall survival compared to CCRT alone in locally advanced cervical cancer.
    • Adjuvant chemotherapy following CCRT failed to confer survival benefits and increased toxicity without efficacy in the OUTBACK trial, while adding concurrent cytotoxic agents has not consistently improved outcomes.
    Read the original sourceCancer management and research